Stefan Rutkowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5003717/publications.pdf

Version: 2024-02-01

170 papers	17,443 citations	31976 53 h-index	14759 127 g-index
175 all docs	175 docs citations	175 times ranked	15095 citing authors

#	Article	IF	Citations
1	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
2	Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 2012, 123, 465-472.	7.7	1,536
3	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	27.8	1,068
4	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	16.8	933
5	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica, 2012, 123, 473-484.	7.7	863
6	Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488, 100-105.	27.8	765
7	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
8	Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone. New England Journal of Medicine, 2005, 352, 978-986.	27.0	682
9	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434.	27.8	520
10	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831.	7.7	478
11	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Journal of Clinical Oncology, 2013, 31, 2927-2935.	1.6	381
12	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature, 2014, 510, 537-541.	27.8	378
13	Medulloblastoma. Nature Reviews Disease Primers, 2019, 5, 11.	30.5	376
14	Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the MYC and MYCN Loci. Journal of Clinical Oncology, 2009, 27, 1627-1636.	1.6	274
15	Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis. Journal of Clinical Oncology, 2010, 28, 4961-4968.	1.6	273
16	Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial. Journal of Clinical Oncology, 2012, 30, 3187-3193.	1.6	270
17	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	10.7	268
18	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263

#	Article	IF	Citations
19	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathologica, 2013, 125, 913-916.	7.7	244
20	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
21	Childhood cancer predisposition syndromesâ€"A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American Journal of Medical Genetics, Part A, 2017, 173, 1017-1037.	1.2	200
22	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
23	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathologica, 2019, 138, 309-326.	7.7	180
24	Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HITâ€˜91. European Journal of Cancer, 2009, 45, 1209-1217.	2.8	173
25	Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro-Oncology, 2011, 13, 669-679.	1.2	149
26	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncology, The, 2015, 16, 569-582.	10.7	147
27	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
28	FSTL5 Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. Journal of Clinical Oncology, 2011, 29, 3852-3861.	1.6	143
29	Adult and Pediatric Medulloblastomas Are Genetically Distinct and Require Different Algorithms for Molecular Risk Stratification. Journal of Clinical Oncology, 2010, 28, 3054-3060.	1.6	136
30	Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro-Oncology, 2009, 11, 201-210.	1.2	125
31	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathologica, 2014, 128, 137-149.	7.7	125
32	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. Journal of Clinical Oncology, 2016, 34, 4151-4160.	1.6	121
33	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica, 2017, 133, 1-3.	7.7	120
34	Childhood medulloblastoma. Critical Reviews in Oncology/Hematology, 2016, 105, 35-51.	4.4	119
35	Intensive chemotherapy improves survival in pediatric highâ€grade glioma after gross total resection: results of the HITâ€GBMâ€C protocol. Cancer, 2010, 116, 705-712.	4.1	116
36	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	7.7	104

#	Article	IF	Citations
37	TP53 Mutation Is Frequently Associated With CTNNB1 Mutation or MYCN Amplification and Is Compatible With Long-Term Survival in Medulloblastoma. Journal of Clinical Oncology, 2010, 28, 5188-5196.	1.6	100
38	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401.	27.8	94
39	Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91. Clinical Cancer Research, 2007, 13, 2651-2657.	7.0	90
40	Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: A prospective observational multicentre study. European Journal of Cancer, 2013, 49, 893-903.	2.8	84
41	Subgroup-specific immune and stromal microenvironment in medulloblastoma. OncoImmunology, 2018, 7, e1462430.	4.6	77
42	Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathologica, 2016, 132, 635-637.	7.7	73
43	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2020, 22, 1006-1017.	1.2	72
44	Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem. Acta Neuropathologica, 2012, 123, 601-614.	7.7	71
45	Expression of FoxM1 Is Required for the Proliferation of Medulloblastoma Cells and Indicates Worse Survival of Patients. Clinical Cancer Research, 2011, 17, 6791-6801.	7.0	70
46	Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. Neuro-Oncology, 2013, 15, 224-234.	1.2	69
47	Quality of Survival and Growth in Children and Young Adults in the PNET4 European Controlled Trial of Hyperfractionated Versus Conventional Radiation Therapy for Standard-Risk Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2014, 88, 292-300.	0.8	68
48	Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. Lancet Oncology, The, 2018, 19, 1602-1616.	10.7	67
49	Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database. Journal of Neurosurgery: Pediatrics, 2010, 6, 137-144.	1.3	64
50	Large cell/anaplastic medulloblastoma: Outcome according to myc status, histopathological, and clinical risk factors. Pediatric Blood and Cancer, 2010, 54, 369-376.	1.5	63
51	cIMPACTâ€NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq1 1 0.784314 rgBT /Overlock 10 27, 851-852.	4.1	63
52	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. Journal of Clinical Oncology, 2020, 38, 2028-2040.	1.6	58
53	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro-Oncology, 2018, 20, 400-410.	1.2	56
54	Medulloblastoma in young children. Pediatric Blood and Cancer, 2010, 54, 635-637.	1.5	52

#	Article	IF	Citations
55	Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial. Oncotarget, 2015, 6, 38827-38839.	1.8	51
56	Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. Journal of Clinical Oncology, 2020, 38, 43-50.	1.6	50
57	Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect <scp>Wnt</scp> activated tumours. Neuropathology and Applied Neurobiology, 2015, 41, 135-144.	3.2	46
58	Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. European Journal of Cancer, 2015, 51, 2634-2642.	2.8	44
59	Molecular characterization of histopathological ependymoma variants. Acta Neuropathologica, 2020, 139, 305-318.	7.7	43
60	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
61	Treatment of Children With Central Nervous System Primitive Neuroectodermal Tumors/Pinealoblastomas in the Prospective Multicentric Trial HIT 2000 Using Hyperfractionated Radiation Therapy Followed by Maintenance Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 863-871.	0.8	39
62	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€“Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39
63	Medulloblastoma. Current Treatment Options in Neurology, 2012, 14, 416-426.	1.8	38
64	Supratentorial ependymoma in childhood: more than just RELA or YAP. Acta Neuropathologica, 2021, 141, 455-466.	7.7	37
65	Strategies to improve the quality of survival for childhood brain tumour survivors. European Journal of Paediatric Neurology, 2015, 19, 619-639.	1.6	36
66	Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas. Cancer Immunology Research, 2019, 7, 1401-1411.	3.4	35
67	Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified. Neuro-Oncology, 2015, 17, 1157-1165.	1.2	33
68	Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. Neuro-Oncology, 2017, 19, now234.	1.2	33
69	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	7.7	33
70	Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 978-985.	0.8	30
71	Metastatic medulloblastoma in adults: Outcome of patients treated according to the HIT2000 protocol. European Journal of Cancer, 2015, 51, 2434-2443.	2.8	30
72	CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. Acta Neuropathologica, 2020, 140, 405-407.	7.7	30

#	Article	IF	Citations
73	Current treatment approaches to early childhood medulloblastoma. Expert Review of Neurotherapeutics, 2006, 6, 1211-1221.	2.8	28
74	p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease. Journal of Neuro-Oncology, 2012, 106, 135-141.	2.9	28
75	Tumors of the Central Nervous System in Children and Adolescents. Deutsches Ärzteblatt International, 2011, 108, 390-7.	0.9	27
76	MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma. Clinical Neuroradiology, 2019, 29, 595-604.	1.9	26
77	c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients. BMC Cancer, 2011, 11, 74.	2.6	22
78	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
79	Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastomaâ€"An Experience From the HIT-REZ 1997 & 2005 Studies. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1019-1024.	0.8	21
80	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. Oncologist, 2019, 24, e921-e929.	3.7	19
81	Returning to daily life: a qualitative interview study on parents of childhood cancer survivors in Germany. BMJ Open, 2020, 10, e033730.	1.9	19
82	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. Neuro-Oncology, 2021, 23, 1012-1023.	1.2	19
83	Parentsâ€™ perception of their childrenâ€™s process of reintegration after childhood cancer treatment. PLoS ONE, 2020, 15, e0239967.	2.5	19
84	Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. Journal of Neuro-Oncology, 2016, 128, 463-471.	2.9	18
85	Detailed Clinical and Histopathological Description of 8 Cases of Molecularly Defined CNS Neuroblastomas. Journal of Neuropathology and Experimental Neurology, 2021, 80, 52-59.	1.7	18
86	MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties. BMC Cancer, 2016, 16, 115.	2.6	17
87	A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma. European Journal of Cancer, 2012, 48, 2028-2036.	2.8	16
88	Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. Lancet Oncology, The, 2018, 19, e419-e428.	10.7	16
89	Health status, health-related quality of life, and socioeconomic outcome in childhood brain tumor survivors: a German cohort study. Neuro-Oncology, 2019, 21, 1069-1081.	1.2	16
90	Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma. Strahlentherapie Und Onkologie, 2021, 197, 674-682.	2.0	16

#	Article	IF	Citations
91	SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma. Cancers, 2021, 13, 6077.	3.7	16
92	Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers, 2022, 14, 374.	3.7	16
93	Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification. PLoS ONE, 2017, 12, e0178351.	2.5	15
94	Fear of progression in parents of childhood cancer survivors: A dyadic data analysis. Psycho-Oncology, 2020, 29, 1678-1685.	2.3	15
95	Nonâ€cerebellar primitive neuroectodermal tumors (PNET): Summary of the Milan consensus and state of the art workshop on marrow ablative chemotherapy with hematopoietic cell rescue for malignant brain tumors of childhood and adolescents. Pediatric Blood and Cancer, 2010, 54, 638-640.	1.5	14
96	Primary central nervous system sarcoma with DICER1 mutationâ€"treatment results of a novel molecular entity in pediatric Peruvian patients. Cancer, 2022, 128, 697-707.	4.1	14
97	Neuropsychological short assessment of disease- and treatment-related intelligence deficits in children with brain tumours. European Journal of Paediatric Neurology, 2015, 19, 298-307.	1.6	13
98	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma â€" A Report From the HIT 2000 Trial. Advances in Radiation Oncology, 2020, 5, 1158-1169.	1.2	13
99	Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. Child's Nervous System, 2013, 29, 1253-1262.	1.1	12
100	Exploring the Potential of a Pretend Play Intervention in Young Patients With Leukemia. Journal of Pediatric Nursing, 2019, 44, e98-e106.	1.5	12
101	Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype. Acta Neuropathologica, 2021, 141, 971-974.	7.7	12
102	Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. Cancers, 2022, 14, 126.	3.7	12
103	Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. Neuro-Oncology, 2022, 24, 1689-1699.	1.2	11
104	Evaluation of dose, volume, and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study. Neuro-Oncology, 2022, 24, 1193-1202.	1.2	11
105	Adults with CNS primitive neuroectodermal tumors/pineoblastomas: results of multimodal treatment according to the pediatric HIT 2000 protocol. Journal of Neuro-Oncology, 2014, 116, 567-575.	2.9	10
106	Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial. Neuro-Oncology Practice, 2017, 4, 161-170.	1.6	9
107	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. American Journal of Neuroradiology, 2019, 40, 1811-1817.	2.4	9
108	Fear of progression in parents of childhood cancer survivors: prevalence and associated factors. Journal of Cancer Survivorship, 2022, 16, 823-833.	2.9	9

#	Article	IF	Citations
109	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study. Cancers, 2022, 14, 471.	3.7	9
110	Development of Randomized Trials in Adults with Medulloblastomaâ€"The Example of EORTC 1634-BTG/NOA-23. Cancers, 2021, 13, 3451.	3.7	8
111	Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response. Child's Nervous System, 2017, 33, 1463-1471.	1.1	7
112	Followâ€up evaluation of a webâ€based pediatric brain tumor board in Latin America. Pediatric Blood and Cancer, 2021, 68, e29073.	1.5	7
113	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. Journal of Neuro-Oncology, 2021, 155, 193-202.	2.9	6
114	Clostridium difficile infection after pediatric solid organ transplantation: a practical single-center experience. Pediatric Nephrology, 2019, 34, 1269-1275.	1.7	5
115	Refining medulloblastoma subgroups. Lancet Oncology, The, 2017, 18, 847-848.	10.7	4
116	EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. Neuro-Oncology, 2018, 20, i72-i72.	1.2	4
117	Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastomaâ€"an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlentherapie Und Onkologie, 2022, 198, 282-290.	2.0	4
118	Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling. Child's Nervous System, 2022, 38, 479-483.	1.1	3
119	Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort. Frontiers in Oncology, 2021, 11, 756025.	2.8	3
120	Reply to J.C. Lindsey et al. Journal of Clinical Oncology, 2011, 29, e348-e349.	1.6	2
121	MB-69RELEVANCE OF CYTOSPIN QUALITY FOR DETECTION OF MICROSCOPIC LEPTOMENINGEAL DISSEMINATION IN MEDULLOBLASTOMA PATIENTS. Neuro-Oncology, 2016, 18, iii112.4-iii113.	1.2	2
122	Group 3 medulloblastoma in a patient with a GYS2 germline mutation and glycogen storage disease 0a. Child's Nervous System, 2018, 34, 581-584.	1.1	2
123	GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. Neuro-Oncology, 2019, 21, ii82-ii82.	1.2	2
124	Effects of the growth pattern of medulloblastoma on short-term neurological impairments after surgery: results from the prospective multicenter HIT-SIOP PNET 4 study. Journal of Neurosurgery: Pediatrics, 2020, 25, 425-433.	1.3	2
125	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. Journal of Neuro-Oncology, 2022, 157, 37-48.	2.9	2
126	ATRT-09. Outcome and therapeutic interventions in relapsed and refractory ATRT â€“ The EU-RHAB perspective. Neuro-Oncology, 2022, 24, i4-i4.	1.2	2

#	Article	IF	Citations
127	Relapse of a group 4 medulloblastoma after 18Âyears as proven by histology and DNA methylation profiling. Child's Nervous System, 2019, 35, 1029-1033.	1.1	1
128	PATH-16. HISTOPATHOLOGICAL EPENDYMOMA VARIANTS ARE ASSOCIATED WITH DISTINCT CLINICAL PARAMETERS AND DNA METHYLATION PATTERNS. Neuro-Oncology, 2019, 21, vi146-vi146.	1.2	1
129	Young children with medulloblastoma: important open questions and the high-risk dilemma. Neuro-Oncology, 2020, 22, 1723-1724.	1.2	1
130	EPEN-39. CLINICAL STRATIFIED TREATMENT OF LOCALIZED PEDIATRIC INTRACRANIAL EPENDYMOMA WITH COMBINED LOCAL IRRADIATION AND CHEMOTHERAPY WITHIN THE PROSPECTIVE, MULTICENTER E-HIT TRIAL â€“ THE MOLECULAR SUBGROUP MATTERS. Neuro-Oncology, 2020, 22, iii315-iii316.	1.2	1
131	EXTH-70. ESTABLISHMENT OF INTRAVENTRICULAR SHH INHIBITION AS A THERAPEUTIC OPTION IN YOUNG PATIENTS WITH MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, vi179-vi179.	1.2	1
132	HGG-16. Final analysis of the HIT-HGG-2007 trial (ISRCTN19852453): Significant survival benefit for pontine and non-pontine pediatric high-grade gliomas in comparison to previous HIT-GBM-C/-D trials.. Neuro-Oncology, 2022, 24, i63-i64.	1.2	1
133	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	1.2	1
134	Early Childhood Medulloblastoma: Prognostic Factors. Pediatric Cancer, 2012, , 173-181.	0.0	0
135	PNR-09EVALUATION OF AGE-DEPENDENT TREATMENT STRATEGIES FOR CHILDREN AND YOUNG ADULTS WITH PINEOBLASTOMA: ANALYSIS OF POOLED SIOP-E AND HEAD START DATA. Neuro-Oncology, 2016, 18, iii8.3-iii8.	1.2	0
136	AT-21INTEGRATED (EPI)GENOMIC ANALYSES IDENTIFY SUB-GROUP SPECIFIC THERAPEUTIC TARGETS IN CNS RHABDOID TUMORS. Neuro-Oncology, 2016, 18, iii6.1-iii6.	1.2	0
137	MBCL-31. A WHOLE CHROMOSOME ABERRATION PHENOTYPE IN NON-WNT/NON-SHH TUMORS PREDICTS OUTCOME WITHIN STANDARD-RISK MEDULLOBLASTOMAS FROM THE HIT-SIOP-PNET4 CLINICAL TRIAL. Neuro-Oncology, 2018, 20, i123-i123.	1.2	0
138	MBCL-29. FEASIBILITY OF SCREENING AND REASONS FOR SCREENING FAILURES IN THE SIOPE PNET 5 MB TRIAL. Neuro-Oncology, 2018, 20, i122-i123.	1.2	0
139	PDCT-03. CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING â€“ A COMPARATIVE OUTCOMES ANALYSIS. Neuro-Oncology, 2019, 21, vi183-vi184.	1.2	0
140	PATH-53. IMMUNOLOGICAL PROFILING OF MUTATIONAL AND TRANSCRIPTIONAL SUBGROUPS IN PEDIATRIC AND ADULT HIGH-GRADE GLIOMAS. Neuro-Oncology, 2019, 21, vi155-vi155.	1.2	0
141	Neuroonkologie. , 2014, , 277-304.		0
142	QOL-24. DIFFERENTIAL IMPACT OF TUMOR LOCATION, LOCAL AND CRANIOSPINAL IRRADIATION ON NEUROPSYCHOLOGICAL LONG-TERM OUTCOME IN CHILDREN WITH MEDULLOBLASTOMA, EPENDYMOMA AND SUPRATENTORIAL PNET: A LONGITUDINAL MULTICENTER OUTCOME ASSESSMENT OF CHILDREN FROM THE HIT-2000 AND HIT-REZ TRIALS. Neuro-Oncology, 2020, 22, iii435-iii436.	1.2	0
143	MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY â€“ A REPORT FROM THE HIT 2000 TRIAL. Neuro-Oncology, 2020, 22, iii389-iii390.	1.2	0
144	LINC-18. FOLLOW-UP EVALUATION OF A WEB-BASED PEDIATRIC BRAIN TUMOR BOARD IN LATIN AMERICA. Neuro-Oncology, 2020, 22, iii381-iii382.	1.2	0

#	Article	IF	Citations
145	QOL-17. BIOLOGICAL CORRELATES OF QUALITY OF SURVIVAL AND NEUROCOGNITIVE OUTCOMES IN MEDULLOBLASTOMA; A META-ANALYSIS OF THE SIOP-UKCCSG-PNET3 AND HIT-SIOP-PNET4 TRIALS. Neuro-Oncology, 2020, 22, iii434-iii434.	1.2	0
146	MBCL-19. CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH DESMOPLASTIC/EXTENSIVE NODULAR MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING â€“ A COMPARATIVE OUTCOMES ANALYSIS OF PROSPECTIVE MULTI-CENTER EUROPEAN AND NORTH AMERICAN TRIALS. Neuro-Oncology, 2020, 22, iii392-iii392.	1.2	0
147	MBCL-21. GERMLINE ELONGATOR MUTATIONS IN SONIC HEDGEHOG MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii392-iii393.	1.2	0
148	MBCL-37. CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH CLASSIC (CLMB) OR ANAPLASTIC/LARGE CELL (A/LCMB) MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING â€“ A COMPARATIVE OUTCOMES ANALYSIS. Neuro-Oncology, 2020, 22, iii396-iii397.	1.2	0
149	RARE-42. PRIMARY INTRACRANIAL SARCOMA WITH DICER1-MUTATION - TREATMENT RESULTS OF A NEW MOLECULAR ENTITY. Neuro-Oncology, 2020, 22, iii451-iii451.	1.2	0
150	MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS. Neuro-Oncology, 2020, 22, iii388-iii388.	1.2	0
151	PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1,000 PEDIATRIC CNS TUMORSâ€”THE MNP 2.0 STUDY. Neuro-Oncology, 2020, 22, iii426-iii426.	1.2	0
152	Diagnostics and Diagnosis of Late Effects in Childhood Brain Tumour Survivors. , 2021, , 239-251.		0
153	PATH-34. MOLECULAR AND CLINICAL HETEROGENEITY WITHIN SPINAL EPENDYMOMAS. Neuro-Oncology, 2021, 23, vi122-vi122.	1.2	0
154	ALK inhibition as a salvage therapy for a relapsed unclassifiable sarcomatous CNS tumor with EML4/ALK fusion in an infant. Pediatric Blood and Cancer, 2022, 69, e29594.	1.5	0
155	MEDB-50. Assessment of cellular radiosensitivity and DNA repair in medulloblastoma cell lines and patient-derivded xenograft slice cultures. Neuro-Oncology, 2022, 24, i117-i118.	1.2	0
156	QOL-28. Clinico-molecular correlates of quality of survival and neurocognitive outcomes in medulloblastoma; a meta-analysis of the SIOP-UKCCSG-PNET3 and HIT-SIOP-PNET4 trials. Neuro-Oncology, 2022, 24, i139-i140.	1.2	0
157	RARE-12. Pineoblastoma of children and young adults in a national population: An analysis of the HIT-MED study cohort. Neuro-Oncology, 2022, 24, i11-i12.	1.2	0
158	MEDB-51. Impact of residual tumor on outcomes in children and adolescents with medulloblastoma in the German HIT-cohort. Neuro-Oncology, 2022, 24, i118-i118.	1.2	0
159	EPEN-13. Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology. Neuro-Oncology, 2022, 24, i41-i41.	1.2	0
160	EPEN-19. Impact of molecular classification on prognosis in children and adolescents with spinal ependymoma: Results from the HIT-MED database. Neuro-Oncology, 2022, 24, i42-i43.	1.2	0
161	MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register. Neuro-Oncology, 2022, 24, i113-i114.	1.2	0
162	MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate. Neuro-Oncology, 2022, 24, i114-i115.	1.2	0

#	Article	IF	Citations
163	MEDB-17. Re-irradiation for recurrent medulloblastoma in a matched cohort: Advantageous especially in patients without resection. Neuro-Oncology, 2022, 24, i108-i108.	1.2	0
164	QOL-10. Treatment-induced leukoencephalopathy in pediatric medulloblastoma survivors and its impact on long-term neurocognitive functioning. Neuro-Oncology, 2022, 24, i135-i135.	1.2	0
165	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	1.2	0
166	MODL-03. Establishment of intraventricular Shh inhibition as a therapeutic option for young patients with medulloblastoma. Neuro-Oncology, 2022, 24, i168-i168.	1.2	0
167	EPEN-27. Epigenetic dissection of spinal ependymomas (SP-EPN) separates tumors with and withoutNF2 mutation. Neuro-Oncology, 2022, 24, i44-i45.	1.2	0
168	MEDB-16. Persistent radiological lesions at the end of primary therapy in childhood medulloblastoma: residual lesion or active residual tumor?. Neuro-Oncology, 2022, 24, i108-i108.	1.2	0
169	EPEN-04. Refinement of molecular and clinical characteristics in a cohort of 1,801 ependymomas. Neuro-Oncology, 2022, 24, i38-i39.	1.2	0
170	EPEN-06. Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. Neuro-Oncology, 2022, 24, i39-i39.	1.2	0